Lupin launches Mirabegron Extended-Release Tablets in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc.

Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of USD 1,019 million in the U.S. (IQVIA MAT February 2024).

Shares of Lupin Limited was last trading in BSE at Rs. 1547.05 as compared to the previous close of Rs. 1593.65. The total number of shares traded during the day was 50239 in over 1401 trades.

The stock hit an intraday high of Rs. 1581.35 and intraday low of 1541.05. The net turnover during the day was Rs. 78174999.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals Mirabegron ExtendedReleaseTablets US